BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21387264)

  • 1. Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults.
    Polishchuk AL; Dubois SG; Haas-Kogan D; Hawkins R; Matthay KK
    Cancer; 2011 Sep; 117(18):4286-93. PubMed ID: 21387264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
    Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
    J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
    Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
    J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
    Zhou MJ; Doral MY; DuBois SG; Villablanca JG; Yanik GA; Matthay KK
    Eur J Cancer; 2015 Nov; 51(16):2465-72. PubMed ID: 26254811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
    Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
    J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].
    Défachelles AS; Cougnenc O; Carpentier P
    Bull Cancer; 2011 May; 98(5):559-69. PubMed ID: 21609890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.
    Kraal KC; van Dalen EC; Tytgat GA; Van Eck-Smit BL
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010349. PubMed ID: 28429876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.
    DuBois SG; Matthay KK
    Nucl Med Biol; 2008 Aug; 35 Suppl 1(Suppl 1):S35-48. PubMed ID: 18707633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
    Kang TI; Brophy P; Hickeson M; Heyman S; Evans AE; Charron M; Maris JM
    J Pediatr Hematol Oncol; 2003 Oct; 25(10):769-73. PubMed ID: 14528098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.
    Matthay KK; DeSantes K; Hasegawa B; Huberty J; Hattner RS; Ablin A; Reynolds CP; Seeger RC; Weinberg VK; Price D
    J Clin Oncol; 1998 Jan; 16(1):229-36. PubMed ID: 9440747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.
    Matthay KK; Panina C; Huberty J; Price D; Glidden DV; Tang HR; Hawkins RA; Veatch J; Hasegawa B
    J Nucl Med; 2001 Nov; 42(11):1713-21. PubMed ID: 11696644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
    French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
    Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
    Trieu M; DuBois SG; Pon E; Nardo L; Hawkins RA; Marachelian A; Twist CJ; Park JR; Matthay KK
    Pediatr Blood Cancer; 2016 Mar; 63(3):436-42. PubMed ID: 26506090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis.
    Bleeker G; Schoot RA; Caron HN; de Kraker J; Hoefnagel CA; van Eck BL; Tytgat GA
    Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1711-7. PubMed ID: 23921531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine.
    Garaventa A; Gambini C; Villavecchia G; Di Cataldo A; Bertolazzi L; Pizzitola MR; De Bernardi B; Haupt R
    Cancer; 2003 Mar; 97(5):1332-8. PubMed ID: 12599242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.
    Matthay KK; Quach A; Huberty J; Franc BL; Hawkins RA; Jackson H; Groshen S; Shusterman S; Yanik G; Veatch J; Brophy P; Villablanca JG; Maris JM
    J Clin Oncol; 2009 Mar; 27(7):1020-5. PubMed ID: 19171714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iodine-131 metaiodobenzylguanidine (131I-mIBG) treatment in relapsed/refractory neuroblastoma.
    Anongpornjossakul Y; Sriwatcharin W; Thamnirat K; Chamroonrat W; Kositwattanarerk A; Utamakul C; Sritara C; Chokesuwattanasakul P; Thokanit NS; Pakakasama S; Anurathapan U; Pongphitcha P; Chotipanich C; Hongeng S
    Nucl Med Commun; 2020 Apr; 41(4):336-343. PubMed ID: 31939898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.
    Quach A; Ji L; Mishra V; Sznewajs A; Veatch J; Huberty J; Franc B; Sposto R; Groshen S; Wei D; Fitzgerald P; Maris JM; Yanik G; Hawkins RA; Villablanca JG; Matthay KK
    Pediatr Blood Cancer; 2011 Feb; 56(2):191-201. PubMed ID: 20830775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
    DuBois SG; Messina J; Maris JM; Huberty J; Glidden DV; Veatch J; Charron M; Hawkins R; Matthay KK
    J Clin Oncol; 2004 Jun; 22(12):2452-60. PubMed ID: 15197208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose
    Kayano D; Wakabayashi H; Nakajima K; Kuroda R; Watanabe S; Inaki A; Toratani A; Akatani N; Yamase T; Kunita Y; Hiromasa T; Takata A; Mori H; Saito S; Araki R; Taki J; Kinuya S
    Ann Nucl Med; 2020 Jun; 34(6):397-406. PubMed ID: 32219730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.